Susquehanna International Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$9.03M Sell
20,221
-63,875
-76% -$29.8M ﹤0.01% 3275
2025
Q4
$38.1M Buy
84,096
+16,413
+24% +$7.07M ﹤0.01% 1596
2025
Q3
$26.5M Buy
67,683
+5,474
+9% +$2.29M ﹤0.01% 1906
2025
Q2
$27.7M Buy
62,209
+21,088
+51% +$9.72M ﹤0.01% 1675
2025
Q1
$19.9M Sell
41,121
-89,284
-68% -$41.6M ﹤0.01% 1745
2024
Q4
$52.5M Buy
130,405
+84,357
+183% +$39.1M 0.01% 1084
2024
Q3
$21.4M Sell
46,048
-33,530
-42% -$16.1M ﹤0.01% 1769
2024
Q2
$37.3M Sell
79,578
-15,402
-16% -$6.69M 0.01% 1196
2024
Q1
$39.7M Sell
94,980
-30,904
-25% -$13.1M 0.01% 1197
2023
Q4
$51.2M Sell
125,884
-73,360
-37% -$27.1M 0.01% 1022
2023
Q3
$69.3M Buy
199,244
+24,958
+14% +$8.73M 0.01% 809
2023
Q2
$61.3M Sell
174,286
-71,067
-29% -$23.9M 0.01% 862
2023
Q1
$77.3M Sell
245,353
-33,648
-12% -$10.1M 0.02% 714
2022
Q4
$80.6M Buy
279,001
+232,658
+502% +$70.9M 0.02% 645
2022
Q3
$13.4M Sell
46,343
-61,778
-57% -$17.8M ﹤0.01% 1823
2022
Q2
$30.5M Buy
108,121
+5,268
+5% +$1.41M 0.01% 1145
2022
Q1
$26.8M Sell
102,853
-233,472
-69% -$55.4M ﹤0.01% 1432
2021
Q4
$73.9M Sell
336,325
-213,904
-39% -$41.6M 0.01% 872
2021
Q3
$99.8M Buy
550,229
+46,682
+9% +$9.11M 0.01% 785
2021
Q2
$102M Buy
503,547
+4,681
+0.9% +$979K 0.01% 777
2021
Q1
$107M Buy
498,866
+247,146
+98% +$54.3M 0.02% 694
2020
Q4
$59.5M Buy
251,720
+232,147
+1,186% +$53.3M 0.01% 909
2020
Q3
$5.33M Sell
19,573
-128,739
-87% -$35.5M ﹤0.01% 2969
2020
Q2
$43.1M Buy
148,312
+77,971
+111% +$21.1M 0.01% 909
2020
Q1
$16.7M Sell
70,341
-47,364
-40% -$10.9M 0.01% 1307
2019
Q4
$25.8M Buy
117,705
+115,618
+5,540% +$23.4M 0.01% 1210
2019
Q3
$354K Sell
2,087
-12,383
-86% -$2.19M ﹤0.01% 7960
2019
Q2
$2.65M Buy
14,470
+11,863
+455% +$2.07M ﹤0.01% 3659
2019
Q1
$480K Buy
+2,607
New +$482K ﹤0.01% 6363
2018
Q3
Sell
-23,588
Closed -$4.2M 10324
2018
Q2
$4.01M Buy
23,588
+19,340
+455% +$3M ﹤0.01% 3005
2018
Q1
$692K Sell
4,248
-121
-3% -$19.8K ﹤0.01% 5980
2017
Q4
$655K Sell
4,369
-5,235
-55% -$775K ﹤0.01% 6094
2017
Q3
$1.46M Buy
9,604
+3,512
+58% +$529K ﹤0.01% 4523
2017
Q2
$785K Sell
6,092
-13,377
-69% -$1.61M ﹤0.01% 5775
2017
Q1
$2.13M Sell
19,469
-13,620
-41% -$1.2M ﹤0.01% 3606
2016
Q4
$2.44M Buy
+33,089
New +$2.69M ﹤0.01% 3656
2016
Q3
Sell
-2,460
Closed -$232K 9121
2016
Q2
$212K Sell
2,460
-54,199
-96% -$4.68M ﹤0.01% 7524
2016
Q1
$4.5M Sell
56,659
-4,871
-8% -$441K ﹤0.01% 2439
2015
Q4
$7.74M Sell
61,530
-99,952
-62% -$12.1M ﹤0.01% 2015
2015
Q3
$16.8M Buy
161,482
+4,596
+3% +$590K 0.01% 1367
2015
Q2
$19.4M Buy
156,886
+46,426
+42% +$5.85M 0.01% 1332
2015
Q1
$13M Sell
110,460
-8,209
-7% -$984K 0.01% 1619
2014
Q4
$14.1M Sell
118,669
-26,788
-18% -$3.02M 0.01% 1651
2014
Q3
$16.3M Sell
145,457
-155,185
-52% -$14.8M 0.01% 1618
2014
Q2
$28.5M Buy
300,642
+130,132
+76% +$9.13M 0.01% 1094
2014
Q1
$12.1M Sell
170,510
-334,940
-66% -$26.5M 0.01% 1790
2013
Q4
$37.6M Buy
505,450
+268,757
+114% +$18.7M 0.02% 838
2013
Q3
$17.9M Buy
236,693
+46,535
+24% +$3.7M 0.01% 1305
2013
Q2
$15.2M Buy
+190,158
New +$14M 0.01% 1369

Other funds holding VRTX

Susquehanna International Group's VRTX Position: Q1 2026 in Review

Susquehanna International Group reduced its Vertex Pharmaceuticals (VRTX) stake by 76% in Q1 2026, selling an estimated $29.8M and leaving 20,221 shares worth $9.03M. The position accounts for ﹤0.01% of the portfolio, ranked #3275.

Susquehanna International Group first reported a position in VRTX in Q2 2013 and has held it in 49 quarters since. The position peaked at $107M in Q1 2021. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Susquehanna International Group held 20,221 shares of Vertex Pharmaceuticals worth $9.03M as of Q1 2026.
  • Susquehanna International Group sold 63,875 Vertex Pharmaceuticals shares in Q1 2026, an estimated $29.8M.
  • Vertex Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #3275 holding.
  • Susquehanna International Group first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 49 quarters since.
  • Susquehanna International Group's Vertex Pharmaceuticals position peaked at $107M in Q1 2021.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.